BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
See today's BioWorld
Home
» Immatics, MD Anderson alliance results in U.S. firm focused on T-cell immunotherapies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immatics, MD Anderson alliance results in U.S. firm focused on T-cell immunotherapies
Aug. 27, 2015
By
Nuala Moran
No Comments
LONDON – The rush into T-cell immunotherapy continues, with Germany's Immatics Biotechnologies GmbH teaming up with MD Anderson Cancer Center in the formation of a $60 million U.S. subsidiary.
BioWorld